|
|
New Products
|
|
|
|
|
Favourable results in highly selected patients
|
|
|
|
|
|
|
|
|
|
Another poorly effective immunosuppressant
|
|
|
|
|
|
|
|
|
|
|
|
Unacceptable risks, in the absence of proven efficacy
|
|
|
|
|
|
|
|
|
|
|
|
Another option, but many long-term unknowns
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
|
|
First-choice treatments
|
|
|
|
|
|
|
|
|
|
Regorafenib: a few extra weeks of life, but with many serious adverse effects
|
|
|
|
Outlook
|
|
|
|
|
Drug companies pay for subscriptions to Prescrire
|
|
|
|
|
|
|
|
|
|
Initial evaluations are positive
|
|
|
|
|
|